Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 5/20 | 0.45 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.43 |
| ▸ | REN | P00797 | 7/20 | 0.41 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PTPRB | P23467 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5019075 | 0.89 | PSMB5 (0.48) | PSMB5PSMB1 | |
| SCHEMBL5018524 | 0.88 | PSMB5 (0.49) | PSMB5PSMB1 | |
| SCHEMBL5025300 | 0.87 | PSMB5 (0.45) | PSMB5PSMB1RENHDAC8 | |
| SCHEMBL5025229 | 0.83 | PSMB5 (0.52) | PSMB5PSMB1HDAC8RXFP1 | |
| SCHEMBL5018504 | 0.79 | PSMB5 (0.45) | PSMB5PSMB1 | |
| SCHEMBL5025228 | 0.79 | HDAC8 (0.44) | PSMB5PSMB1RENHTRA1HDAC8 | |
| SCHEMBL5019069 | 0.78 | PSMB5 (0.47) | PSMB5PSMB1HDAC8 | |
| SCHEMBL13290343 | 0.74 | HDAC4 (0.51) | HDAC8SCN9A | |
| SCHEMBL5018280 | 0.73 | ADCY6 (0.42) | HDAC8SCN9A | |
| SCHEMBL10271682 | 0.73 | MCL1 (0.40) | PSMB5PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054102-A2 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | PSMB5 865/4885PSMB1 556/4885REN 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.